<DOC>
	<DOCNO>NCT01701739</DOCNO>
	<brief_summary>This open-label , two-period , fixed-sequence study investigate pharmacokinetics safety multiple dos aleglitazar single dose digoxin healthy volunteer . In period 1 , volunteer receive single dose digoxin , period 2 volunteer receive multiple dos aleglitazar single dose digoxin . The anticipated time study treatment one month .</brief_summary>
	<brief_title>A Pharmacokinetics Study Aleglitazar Combination With Digoxin Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Digoxin</mesh_term>
	<criteria>Healthy volunteer , 1855 year age , inclusive Body mass index ( BMI ) 18.0 30.0 kg/m2 inclusive . Females must either surgically sterile postmenopausal least one year , childbearing potential , must use two acceptable method contracepetion Volunteer normally drink three cup coffee/tea/caffeinated soft drink per day willing stop drinking coffee/tea/caffeinated soft drink study Any clinically relevant abnormal laboratory test result screen Day 1 Has take prescribe herbal/over counter medication within 2 week prior first dose A history clinically significant gastrointestinal , cardiovascular , musculoskeletal , endocrine , hematological , psychiatric , renal , hepatic , bronchopulmonary neurological condition lipid metabolism disorder . Infection human immunodeficiency virus ( HIV ) , hepatitis B , hepatitis C An average alcohol intake 14 unit per week A known permanent unexplained elevation serum transaminases &gt; 1.5 time upper limit normal A positive screen drug abuse Acute infection require treatment within 4 week prior screen Diagnosed treated malignancy within past 5 year</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>